Viridian Therapeutics Inc

NASDAQ: VRDN
$19.62
-$0.17 (-0.9%)
Closing Price on November 21, 2024

VRDN Stock Chart and Intraday Price

VRDN Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry SERVICES-MEDICAL LABORATORIES
Address 6200 LOOKOUT ROAD, BOULDER, CO, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 1,248.45M USD
Shares Outstanding 62,768,000
Viridian Therapeutics, Inc., based in Waltham, Massachusetts, is a biotechnology firm focused on developing treatments for serious and rare diseases. Its leading projects include VRDN-001, a monoclonal antibody for thyroid eye disease, now in Phase 3 trials, and VRDN-003, a next-generation antibody with potential for the same condition. The company also explores treatments for autoimmune diseases through its preclinical programs VRDN-006 and VRDN-008. Founded in 2010 and originally known as Miragen Therapeutics, it rebranded to Viridian Therapeutics in 2021.

VRDN Articles

Last Week's 3 Biotech IPOs Prompt Huge Insider Buying
IPOs at three biotechs last week tempted insiders to make huge purchases of shares. This effect spilled over into buying at a couple of other biotechs as well.
Trey Thoelcke
Published:

Huge Insider Buys From Warren Buffett, Jack Ma, Carlos Slim and More
Recent insider buying has been highlighted by purchases by Warren Buffett, Jack Ma, Carlos Slim, and John Paulson. Biotechs tempted insiders, as did public offerings.
Trey Thoelcke
Published: